Abstract: A Streptococcus suis (S. suis) vaccine is provided. For the S. suis vaccine, an antigen is a protein with an amino acid sequence shown in SEQ ID NO: 2. A preparation method of the S. suis vaccine is provided, including the following steps: mixing a white oil and aluminum stearate to obtain a white oil adjuvant; adding poly sorbate 80 to an aqueous solution of the protein with the amino acid sequence shown in SEQ ID NO: 2, and thoroughly mixing to obtain an antigen solution; and mixing the antigen solution with the white oil adjuvant according to a volume ratio of (0.5-1.5):2, and emulsifying to obtain the S. suis vaccine. An animal immunized with the S. suis vaccine of the present disclosure can effectively resist the attack of S. suis serotype 2, 3, and 31, with a vaccine protection rate as high as 100%.

Abstract: Provided herein are tuberculatin analogs that are useful as antivirals, such as anti-HIV, anti-coronaviral, anti-Ebola viral, and anti-influenza viral agents and methods of use thereof.

Abstract: An ultrasonication apparatus is provided for improving catheter function. The ultrasonication apparatus includes a transducer configured to produce ultrasonic waves for ultrasonication and a chamber for containing a fluid having a passage for receiving a catheter. The chamber is adapted to receive the ultrasonic waves from the transducer.

Abstract: An ultrasonication apparatus is provided for improving catheter function. The ultrasonication apparatus includes a transducer configured to produce ultrasonic waves for ultrasonication and a chamber for containing a fluid having a passage for receiving a catheter. The chamber is adapted to receive the ultrasonic waves from the transducer.

Abstract: This invention relates to statistically significant methods for metabolomics data analysis that incorporate the structure information of metabolites. Understanding of disease pathogenesis and drug effects, as well as prediction of variation in drug response can be achieved by analyzing quantitative data measuring metabolomics biomarker profiles from biological samples. This invention is to boost the statistical power of analyzing metabolomics data. The comprising methods may include retrieving information of metabolites' chemical structures, converting them into structural data, and integrating the structural data into analysis of metabolite concentration data to improve the evaluation of metabolites and to better identify metabolomics signatures.

Abstract: Disclosed herein are markers for diagnosing Alzheimer's Disease and/or mild cognitive impairment, for predicting risk of developing Alzheimer's Disease and/or mild cognitive impairment, and for monitoring the efficacy of treatment for Alzheimer's Disease and/or mild cognitive impairment. Also disclosed herein are methods of diagnosing Alzheimer's Disease and/or mild cognitive impairment in a subject in need thereof, for predicting risk of developing Alzheimer's Disease and/or mild cognitive impairment in a subject in need thereof, and for monitoring the efficacy of a treatment for Alzheimer's Disease and/or mild cognitive impairment in the subject.